Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) Target Price at $10.60

Shares of Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $10.20.

A number of analysts recently weighed in on the stock. Piper Sandler lowered their target price on shares of Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research note on Tuesday. Wells Fargo & Company lowered their price objective on Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 21st. Citigroup cut their target price on Health Catalyst from $10.50 to $10.00 and set a "buy" rating for the company in a research report on Friday, January 10th. Stephens upped their price target on Health Catalyst from $7.00 to $9.00 and gave the company an "equal weight" rating in a research report on Thursday, November 14th. Finally, KeyCorp upgraded Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective for the company in a research note on Wednesday, January 8th.

Health Catalyst Stock Performance

Health Catalyst stock traded down $0.25 on Friday, hitting $5.50. The company's stock had a trading volume of 572,705 shares, compared to its average volume of 789,959. Health Catalyst has a one year low of $5.32 and a one year high of $10.31. The firm has a market cap of $334.66 million, a P/E ratio of -4.07 and a beta of 1.34. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a fifty day moving average price of $6.74 and a 200-day moving average price of $7.40.

Insiders Place Their Bets

In other news, insider Kevin Lee Freeman sold 7,500 shares of the firm's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $8.94, for a total value of $67,050.00. Following the transaction, the insider now owns 236,950 shares of the company's stock, valued at approximately $2,118,333. This trade represents a 3.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Duncan Gallagher sold 4,500 shares of the business's stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $6.98, for a total transaction of $31,410.00. Following the sale, the director now directly owns 74,438 shares of the company's stock, valued at approximately $519,577.24. This trade represents a 5.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,169 shares of company stock valued at $629,068 in the last 90 days. 2.50% of the stock is currently owned by insiders.

Institutional Trading of Health Catalyst

Institutional investors have recently bought and sold shares of the business. Harbor Capital Advisors Inc. grew its stake in shares of Health Catalyst by 21.3% during the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company's stock worth $96,000 after purchasing an additional 2,064 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Health Catalyst by 10.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company's stock worth $148,000 after buying an additional 2,164 shares during the period. Creative Planning increased its stake in shares of Health Catalyst by 13.2% in the 3rd quarter. Creative Planning now owns 21,348 shares of the company's stock valued at $174,000 after acquiring an additional 2,486 shares during the last quarter. Probity Advisors Inc. raised its position in shares of Health Catalyst by 13.3% in the 3rd quarter. Probity Advisors Inc. now owns 23,045 shares of the company's stock valued at $188,000 after acquiring an additional 2,699 shares during the period. Finally, Legato Capital Management LLC boosted its stake in Health Catalyst by 3.7% during the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company's stock worth $622,000 after acquiring an additional 3,171 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company's stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.